YD Bio (YDES)
Builds cancer-testing and ophthalmology programs alongside clinical-trial drug supply.
Something off on this page? Send us feedback.
Develops blood-based cancer tests and ophthalmology programs while supplying clinical-trial drugs and related products. Its model pairs licensed diagnostic technology and partner-led development with legacy commercial activity.
Blood-based tests using cell-free DNA methylation analysis target pancreatic, breast, and other cancers. The pipeline also includes exosome and stem-cell programs for ophthalmology, while the established commercial business supplies clinical-trial drugs and related products for pharmaceutical company customers.
Development is organized around partnerships, including EG Biomed's U.S.-based DNA-methylation laboratory and 3D Global Biotech's eye-care solutions. The company is Taiwan-founded and now Nasdaq-listed, with licensed diagnostic rights spanning the U.S., Europe, and Asia. Recurring losses and negative operating cash flows are expected to continue until an adequate revenue base is reached.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Dec 31, 2025Cash & short-term investments $6.0M · Total debt $6.8K · Total assets $13.8M · Shareholders' equity −$2.9M
- Revenue
- $0
- Operating income
- −$389.2K
- Net income
- −$2.2M
No dividends on record.
| Institutions8 holders · as of Mar 31, 2026 | 0.23% | 159.5K shares | |
| Insiders4 holders · as of Jul 1, 2026 | 76.86% | 54.44M shares | |
| Otherremainder | 22.91% | 16.23M shares |
70.83M company shares as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Ethan PhD ShenInsiderdirector, officer: CEO | 76.72% | 54.35M | Form 4filed Mar 18, 2026 ↗ |
Geode Capital Management, LLCInstitution | 0.09% | 60,236 | 13Fas of Mar 31, 2026 |
Shao-Ta LuInsiderdirector | 0.08% | 58,981 | Form 4filed Jul 1, 2026 ↗ |
Cerity Partners LLCInstitution | 0.05% | 32,406 | 13Fas of Mar 31, 2026 |
Bo-Xiang ZhangInsiderdirector, officer: Chief Medical Officer | 0.04% | 31,141 | Form 4filed Mar 27, 2026 ↗ |
| See all 12 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
- GRAIL
Methylation-based blood testing for multi-cancer early detection
- Guardant Health
Methylation-based blood tests for colorectal and multi-cancer screening
- Alcon
OTC artificial tears and prescription treatments for dry eye
- Regeneron
Approved retinal therapies for wet AMD and macular edema
- Johnson & Johnson
Large-scale ACUVUE contact-lens portfolio with eye-care products
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| YD Bio | $3.74 | −4.10% | $266.3M | — | — | — | — |
| GRAIL | $81.41 | +1.17% | $3.46B | — | — | 20.9 | +25.7% |
| Guardant Health | $163.05 | +0.02% | $21.88B | — | — | 18.5 | +44.3% |
| Alcon | $72.68 | +0.62% | $35.23B | 55.6 | 18.8 | 3.3 | +7.5% |
| Regeneron | $851.82 | −0.02% | $87.78B | 21.1 | 14.1 | 5.7 | +16.7% |
| Johnson & Johnson | $274.78 | −0.17% | $663.23B | 31.9 | 23.1 | 6.8 | +6.6% |
| Median | 31.9 | 18.8 | 6.8 | +16.7% |